SERB Deal Lifts Hansa Biopharma's Q3 Revenue to SEK 143 Million

Hansa Biopharma AB posted third-quarter 2026 revenue of SEK 143.0 million, up from SEK 30.8 million a year earlier, as its Idefirix licensing agreement with SERB Pharmaceuticals shifted the Swedish drugmaker's revenue mix.

Basic and diluted earnings per share were negative SEK 1.75, unchanged from the third quarter of 2025. Hansa's loss for the period was SEK 178.5 million, compared with SEK 148.3 million a year earlier. Cash and cash equivalents totaled SEK 1.337 billion on Sept. 30, 2026, versus SEK 252.1 million on Sept. 30, 2025.

The quarter's revenue included SEK 121.6 million in license revenue, SEK 20.8 million in supply and service revenue, and SEK 0.6 million in contract revenue. The agreement significantly changed the revenue mix, making comparison with the year-earlier quarter less direct.

The license revenue included a portion of the €110 million upfront payment for Idefirix rights in Europe and the MENA region, recognized over time through December 2028. The agreement closed July 1, and Hansa received the upfront payment July 8. It also includes an additional €5 million payment upon acceptance of a filing for full approval.

“This was a quarter of strong execution for Hansa,” CEO Renée Aguiar-Lucander said.